Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis

Blood (2019) 134 (Supplement_1): 4341.

https://doi.org/10.1182/blood-2019-128854

Published: 2019

Journal Articles

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy

Judith Lind, PhD, Felix Czernilofsky, Sonia Vallet, MD, Fengjuan Fan, PhD, Martin Sattler, PhD, Latifa Bakiri, Erwin F Wagner, PhD, Martin Percherstorfer, MD, Klaus Podar, MD PhD

Blood (2019) 134 (Supplement_1): 4415.

https://doi.org/10.1182/blood-2019-125202

Published: 2019

Journal Articles

The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment

Fengjuan Fan, PhD, Sonia Vallet, MD, Martin Sattler, PhD, Giovanni Tonon, MDPhD, Muhammad Hasan Bashari, Latifa Bakiri, PhD, Hartmut Goldschmidt, MD, Erwin F. Wagner, PhD, Dirk Jaeger, MD, Klaus Podar, MD PhD

Blood (2014) 124 (21): 3446.

https://doi.org/10.1182/blood.V124.21.3446.3446

Published: 2014

Journal Articles

Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1 128–350 Triggers MM Cell Death V ia c- Jun Upregulation

Fengjuan Fan, PhD, Giovanni Tonon, MD PhD, Martin Sattler, PhD, Alexander Schimming, Hartmut Goldschmidt, MD, PhD, Joseph Opferman, Ph.D, Kenneth C. Anderson, MD, Dirk Jaeger, MD, Klaus Podar, MD, PhD

Blood (2012) 120 (21): 3959.

https://doi.org/10.1182/blood.V120.21.3959.3959

Published: 2012

Journal Articles

Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma.

Klaus Podar, MD, PhD, Alexander Zimmerhackl, DI, Ursula Hainz, PhD, Mariateresa Fulciniti, PhD, Sonia Vallet, MD., Dian Olsen, MSc, Yu-Tzu Tai, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, Ph.D, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 1850.

https://doi.org/10.1182/blood.V114.22.1850.1850

Published: 2009

Journal Articles

BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells.

Margret S. Rodrigues, PhD, Jeffrey R. Gonneville, BS, Klaus Podar, MD, PhD, David M. Weinstock, MD, James D. Griffin, MD, Martin Sattler, PhD

Blood (2007) 110 (11): 2937.

https://doi.org/10.1182/blood.V110.11.2937.2937

Published: 2007

Journal Articles

Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.

Marc S. Raab, MD, Klaus Podar, MD, PhD, Jing Zhang, MSc, Giovanni Tonon, MD, Johannes H. Fruehauf, MD, Iris Breitkreutz, MD, Boris K. Lin, MD, PhD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 258.

https://doi.org/10.1182/blood.V110.11.258.258

Published: 2007

Journal Articles

The Tyrophostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo.

Klaus Podar, MD, PhD, Jing Zhang, MSc, Marc S. Raab, MD, Sonia Vallet, MD, Mariateresa Fulciniti, MSc, Martin Sattler, PhD, Yutaka Ikeda, MD, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 2507.

https://doi.org/10.1182/blood.V110.11.2507.2507

Published: 2007

Journal Articles

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Blood (2007) 110 (11): 256.

https://doi.org/10.1182/blood.V110.11.256.256

Published: 2007

Journal Articles

Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1.

Steven Le Gouill, MD, PhD, Klaus Podar, MD PhD, Jing Zhang, Teru Hideshima, MD PhD, Martine Amiot, PhD, Chauhan Dharminder, PhD, Jean-Luc Harousseau, MD, Kenneth Anderson, MD

Blood (2007) 110 (11): 1501.

https://doi.org/10.1182/blood.V110.11.1501.1501

Published: 2007

Journal Articles

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Teru Hideshima, MD, PhD, Noopur Raje, MD, Ruben Carrasco, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Tanyel Kiziltepe, PhD, Sonia Valet, MD, Samantha Pozzi, MD, Dharminder Chauhan, PhD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 670.

https://doi.org/10.1182/blood.V110.11.670.670

Published: 2007

Journal Articles

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Hiroshi Yasui, MD, PhD, Laurence Catley, MD, Noopur Raje, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Klaus Podar, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Sonia Vallet, MD, Tanyel Kizitepe, PhD, Enrique Ocio, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3410.

https://doi.org/10.1182/blood.V108.11.3410.3410

Published: 2006

Journal Articles

Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).

Marc S. Raab, MD, Klaus Podar, MD, PhD, Jing Zhang, MSc, Douglas McMillin, PhD, Iris Breitkreutz, MD, Yu-Tzu Tai, PhD, Boris Lin, MD, PhD, Irene Ghobrial, MD, Nikhil Munshi, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3466.

https://doi.org/10.1182/blood.V108.11.3466.3466

Published: 2006

Journal Articles

Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, James E. Bradner, MD, Hiroshi Yasui, MD, PhD, Noopur Raje, MD, Dharminder Chauhan, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Constantine Mitsiades, MD, PhD, Paul G. Richardson, MD, Ralph Mazitschek, PhD, Stuart L. Schreiber, PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3426.

https://doi.org/10.1182/blood.V108.11.3426.3426

Published: 2006

Journal Articles

Identification of Novel Antigens with Induced Immune Response in MGUS.

Simona Blotta, MD, Hiroshi Yasui, MD, Pierfrancesco Tassone, MD, Roberto Bellucci, PhD, Yu-Tzu Tai, PhD, Rao Prabhala, PhD, Masood A. Shammas, PhD, Pierosandro Tagliaferri, MD, Klaus Podar, MD, PhD, Paola E. Neri, MD, Mariateresa Fulciniti, PhD, Vidit Munshi, Dharminder Chauhan, PhD, Teru Hideshima, MD, PhD, Salvatore Venuta, MD, PhD, Jerome Ritz, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 655.

https://doi.org/10.1182/blood.V108.11.655.655

Published: 2006

Journal Articles

Perifosine, an Oral Bioactive Novel Alkyl-Phospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Laurence Catley, MD, Hiroshi Yasui, MD, PhD, Kenji Ishitsuka, MD, PhD, Noopur Raje, MD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Nikhil C. Munshi, MD, Dharminder Chauhan, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 250.

https://doi.org/10.1182/blood.V106.11.250.250

Published: 2005

Journal Articles

The JAK Inhibitor INCB20 Induces Antiproliferative and Apoptotic Effects in Human Myeloma Cells In Vitro and In Vivo .

Renate Burger, PhD, Steven Legouill, MD, Yu-Tzu Tai, PhD, Reshma Shringarpure, PhD, Klaus Podar, MD, PhD, Laurence Catley, MD, Pierfrancesco Tassone, MD, Paola Neri, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Eian Caulder, BS, Kris Vaddi, PhD, Claire L. Neilan, PhD, Martin Gramatzki, MD, Jordan S. Fridman, PhD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 3357.

https://doi.org/10.1182/blood.V106.11.3357.3357

Published: 2005

Journal Articles

Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.

Yu-Tzu Tai, PhD, Laurence Catley, MD, Xian-Feng Li, MS, Rory Coffey, BS, Iris Breitkreutz, MD, Jooeun Bae, PhD, Klaus Podar, MD, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Robert Schlossman, MD, Paul Richardson, MD, Steven P. Treon, MD, PhD, Iqbal S. Grewal2, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 5150.

https://doi.org/10.1182/blood.V106.11.5150.5150

Published: 2005

Journal Articles

Targeting Src- Family Kinase Activation and Downstream Molecular Events To Overcome MM Cell Growth, Survival, and Drug- Resistance.

Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Dean Abtahi, BS, Marc S. Raab, MD, Hiroshi Yasui, MD, PhD, Kenji Ishitsuka, MD, PhD, Norihiko Shiraishi, PhD, Laurence P. Catley, MD, Martin Sattler, PhD, Noopur Raje, MD, Teru Hideshima, MD, PhD, Dharminder Chauhan, JD, PhD

Blood (2005) 106 (11): 1583.

https://doi.org/10.1182/blood.V106.11.1583.1583

Published: 2005

NARROW

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy

The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment

Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1 128–350 Triggers MM Cell Death V ia c- Jun Upregulation

Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma.

BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells.

Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.

The Tyrophostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo.

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1.

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).

Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.

Identification of Novel Antigens with Induced Immune Response in MGUS.

Perifosine, an Oral Bioactive Novel Alkyl-Phospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma (MM) Cells.

The JAK Inhibitor INCB20 Induces Antiproliferative and Apoptotic Effects in Human Myeloma Cells In Vitro and In Vivo .

Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.

Targeting Src- Family Kinase Activation and Downstream Molecular Events To Overcome MM Cell Growth, Survival, and Drug- Resistance.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only